IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 59.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 125,450 shares of the company’s stock after selling 180,904 shares during the quarter. Corient Private Wealth LLC’s holdings in IDEXX Laboratories were worth $51,866,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.7 %

Shares of NASDAQ IDXX opened at $422.36 on Tuesday. The stock has a market cap of $34.35 billion, a P/E ratio of 39.58, a PEG ratio of 3.41 and a beta of 1.39. The business’s fifty day simple moving average is $437.89 and its 200-day simple moving average is $446.30. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insiders Place Their Bets

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.